The CCDC127 Knockout AGS Polyclonal Cells represent a CRISPR/Cas9-engineered polyclonal cell population in which the CCDC127 gene has been disrupted to create a loss-of-function model. This product provides a genetically modified AGS human gastric adenocarcinoma cell population with CCDC127 ablation, enabling functional dissection of the encoded coiled-coil domain-containing protein in a cancer-relevant background.
The AGS host cell line is a widely studied human gastric epithelial adenocarcinoma model originally derived from a 54-year-old female patient. These adherent cells retain key characteristics of gastric carcinoma and are extensively employed in gastric cancer research, including studies of tumor cell signaling, proliferation, migration, and drug response. Their established use in biomedical research makes them a valuable platform for investigating gene function in the context of gastric malignancy.
CCDC127 is a gene encoding a coiled-coil domain-containing protein with predicted roles in microtubule cytoskeleton organization and mitotic spindle assembly. Although its upstream regulators and downstream targets remain largely uncharacterized, CCDC127 is proposed to interact with core microtubule-associated components, including tubulin, gamma-tubulin, and centrosomal proteins. These molecular associations suggest that CCDC127 may contribute to spindle pole integrity and chromosome segregation during mitosis, positioning it as a potential regulator of cell division fidelity.
In the AGS gastric cancer context, disruption of CCDC127 may impair mitotic progression and microtubule-dependent processes, offering a physiologically relevant model to investigate how alterations in spindle dynamics influence cancer cell behavior. This polyclonal knockout population allows examination of CCDC127 function in a heterogeneous cell pool, reflecting the diversity present in gastric tumors and facilitating studies on the gene??s role in proliferation, genomic stability, and response to chemotherapeutic agents.
Researchers can employ this model in a variety of downstream assays, including Western blotting and RT-qPCR for confirmation of CCDC127 expression loss, immunofluorescence to visualize spindle and microtubule defects, cell proliferation and colony formation assays, flow cytometry for cell cycle distribution, migration assays, and drug sensitivity profiling. The polyclonal knockout cells are particularly suited for identifying CCDC127 interaction partners through co-immunoprecipitation and mass spectrometry, and for screening potential therapeutic compounds targeting mitotic vulnerabilities. For detailed product specifications and technical support, please contact Ascent Research.
